All In Biotech

Drug Trial Radar · NCT05200442

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

A Phase 1b/2 Study of AVUTOMETINIB and Cetuximab in Participants With Advanced KRAS Mutated Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

53

Planned (sponsor's estimate)

Start

Aug 22, 2022

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Lead sponsor
University of ChicagoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Verastem, Inc.
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatment or individuals who cannot take/tolerate previous treatments. If you choose to participate, your time in this research will last up to 24 months.

Conditions

  • Colorectal Cancer
  • Colorectal Adenocarcinoma
  • Colorectal Cancer Metastatic
  • Advanced Colorectal Carcinoma
  • Advanced Colorectal Adenocarcinoma

Interventions

  • VS-6766/avutometinibDrug

    An oral anti-cancer medication.

  • CetuximabDrug

    A chemotherapy drug used to treat head, neck and colorectal cancer.

  • Pill DiaryOther

    A diary where participants in phase 2 of study will log their medications and times they are taken on study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I Primary Objective: Maximum Tolerated Dose (MTD) of VS-6766 combined with CetuximabTime frame: 2 years
  2. Phase 2 Primary Objective: Objective Response Rate of Participants Who Take Phase I /MTD Dose of VS-6766 combined with CetuximabTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Chicago Medical Center

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.